MedPath

Interventional study for severe obesity patients with non-alcoholic fatty liver disease (NAFLD) by Mazindol

Not Applicable
Conditions
Severe obesity patient with non-alcoholic fatty liver disease
Registration Number
JPRN-UMIN000022879
Lead Sponsor
Gunma University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Allergy to Mazindol, Glaucoma, Severe heart disease, Severe diabetes mellitus, Severe liver and renal disturbance, Severe hypertension, Cerebrovascular disease, Mental illness, Seizure, Alcohol and drug abuse, MAO inhibitor, Pregnant woman

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in body weight 12 weeks after administration
Secondary Outcome Measures
NameTimeMethod
Improvement in liver function 12 weeks after administration
© Copyright 2025. All Rights Reserved by MedPath